Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polatuzumab vedotin + R-GemOx vs R-GemOx in relapsed/refractory diffuse large B-cell lymphoma
2018-003727-10Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2020
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Roche. Started Jan 2020; status: active.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2018-003727-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003727-10.